{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-063348","form_type":"8-K","ticker":"HCWB","cik":"0001828673","company_name":"HCW Biologics Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.811380+00:00","generated_at":"2026-06-08T03:58:04.802849+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"HCW Biologics Q3 net loss widens to $4.9M; cash $11.2M; Phase 1 data positive","bullets":["Revenue fell to $853K from $1.8M YoY; licensee Wugen limiting purchases for remainder of 2023.","Net loss increased 26% YoY to $4.9M; G&A jumped 107% to $3.6M due to Altor/NantCell litigation legal fees.","Cash and equivalents $11.2M at Sep 30, 2023; company believes capital sufficient through end of 2024.","Phase 1 trial of HCW9218: 50% of evaluable patients had stable disease; dose-dependent TGF-β reduction; well tolerated.","Expects to complete initial phase of both cancer studies by early 2024; plans to submit IND for HCW9302 by end of 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-063348","json":"https://secwatch.observer/filing/0000950170-23-063348.json","markdown":"https://secwatch.observer/filing/0000950170-23-063348.md","text":"https://secwatch.observer/filing/0000950170-23-063348.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828673/000095017023063348/0000950170-23-063348-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828673/000095017023063348/hcwb-20231114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:58:04.802849+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e9df844fe7bb77ac09352f7775e17489c60782fc","claim":"HCW Biologics Inc. reported quarter ended September 30, 2023 results: revenue $853,102, net income $4.9 million.","evidence_excerpt":"level for future Phase 2 studies of HCW9218. 2 Third Quarter 2023 Financial Results: • Revenues: Revenues for the quarter ended September 30, 2022 and 2023 were $1.8 million and $853,102, respectively. Revenues for the nine months ended September 30, 2022 and 2023 were $5.4 million and $1.5 million, respectively. Revenues were derived exclusively from the sale of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828673/000095017023063348/0000950170-23-063348-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2023"},{"label":"Revenue","value":"$853,102"},{"label":"Net income","value":"$4.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}